Auranofin Is an Apoptosis-Simulating Agent with in Vitro and in Vivo Anti-leishmanial Activity
Zeitschriftenaufsatz
Autoren/Herausgeber
Forschungsfelder
Es wurden keine entsprechenden Inhalte gefunden.
Details zur Publikation
Autorenliste: Sharlow ER, Leimgruber S, Murray S, Lira A, Sciotti RJ, Hickman M, Hudson T, Leed S, Caridha D, Barrios AM, Close D, Grogl M, Lazo JS
Verlag: American Chemical Society
Jahr der Veröffentlichung: 2014
Bandnummer: 9
Heftnummer: 3
Erste Seite: 663
Letzte Seite: 672
Seitenumfang: 10
ISSN: 1554-8929
Sprachen: Englisch-Vereinigtes Königreich (EN-GB)
In Web of Science anzeigen | Webseite des Verlags anzeigen | Zitierende Artikel in Web of Science anzeigen
Beschreibung
Cutaneous leishmaniasis remains ignored in therapeutic drug discovery programs worldwide. This is mainly because cutaneous leishmaniasis is frequently a disease of impoverished populations in countries where funds are limited for research and patient care. However, the health burden of individuals in endemic areas mandates readily available, effective, and safe treatments. Of the existing cutaneous leishmaniasis therapeutics, many are growth inhibitory to Leishmania parasites, potentially creating dormant parasite reservoirs that can be activated when host immunity is compromised, enabling the reemergence of cutaneous leishmaniasis lesions or worse spread of Leishmania parasites to other body sites. To accelerate the identification and development of novel cutaneous leishmaniasis therapeutics, we designed an integrated in vitro and in vivo screening platform that incorporated multiple Leishmania life cycles and species and probed a focused library of pharmaceutically active compounds. The objective of this phenotypic drug discovery platform was the identification and prioritization of bona fide cytotoxic chemotypes toward Leishmania parasites. We identified the Food and Drug Administration-approved drug auranofin, a known inhibitor of Leishmania promastigote growth, as a potent cytotoxic anti-leishmanial agent and inducer of apoptotic-like death in promastigotes. Significantly, the anti-leishmanial activity of auranofin transferred to cell-based amastigote assays as well as in vivo murine models. With appropriate future investigation, these data may provide the foundation for potential exploitation of gold(I)-based complexes as chemical tools or the basis of therapeutics for leishmaniasis. Thus, auranofin may represent a prototype drug that can be used to identify signaling pathways within the parasite and host cell critical for parasite growth and survival.
Schlagwörter
Es wurden keine entsprechenden Inhalte gefunden.
Dokumente
Es wurden keine entsprechenden Inhalte gefunden.
|
|